ASCO 2019: Overall Survival With or Without Enzalutamide for Prostate Cancer
Posted: Monday, June 3, 2019
As reported in the Plenary Session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract LBA2), overall survival for patients with metastatic hormone-sensitive prostate cancer improved with enzalutamide as a supplement to testosterone suppression with or without docetaxel. Ian D. Davis, MBBS, PhD, of Monash University, Australia, and colleagues performed the ENZAMET study as an Australian and New Zealand Urogenital and Prostate Cancer Trials Group–led international cooperative group trial. Many experts predict these actionable results will change clinical practice for this patient population. After 3 years, 80% of the men wo received enzalutamide along with testosterone suppression were alive, compared with 72% of the men who received standard care.
“These findings are truly practice-informing, adding an effective drug option in treating [metastatic hormone-sensitive prostate cancer,” stated coauthor Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute’s Lank Center for Genitourinary Oncology, who presented these results at the ASCO meeting.
This phase III randomized trial focused on the data of 1,125 patients who were randomly assigned to 2 groups between March 2014 and March 2017. Some patients received testosterone suppression plus enzalutamide, whereas others received testosterone suppression plus nonsteroidal antiandrogen therapy.
At a median follow-up of 33 months, patients who received enzalutamide had longer overall survival. After 3 years, 64% of patients who received enzalutamide and 36% of patients who received nonsteroidal antiandrogen therapy were still receiving therapy. A total of 42% of patients who received enzalutamide and 34% of patients who received nonsteroidal antiandrogen therapy experienced serious adverse events within 30 days of starting treatment.
“Enazlutamide significantly improved overall survival when added to testosterone suppression with or without docetaxel in metastatic hormone-sensitive prostate cancer,” Dr. Davis and colleagues concluded. “The benefits appeared lower in those planned to receive early docetaxel.”
Disclosure: The study authors’ disclosure information may be found at coi.asco.org.
